Synthesis and pharmacological screening of 4, 6-substituted di-(phenyl) pyrimidin-2-amines  by Kumar, Nitin et al.
Arabian Journal of Chemistry (2017) 10, S877–S880King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis and pharmacological screening of
4, 6-substituted di-(phenyl) pyrimidin-2-amines* Corresponding author. Mobile: +919717893319, +919310497960.
E-mail addresses: nitinvermakr@gmail.com (N. Kumar),
sushmadrabu@gmail.com (S. Drabu), shalinichem@rediffmail.com
(K. Shalini).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2012.12.023
1878-5352 ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Nitin Kumar a,*, Sushma Drabu b, Kumari Shalini aa Department of Pharmaceutical Technology, MIET, NH-58, Bypass Road, Baghpat Crossing, Meerut-250005, U.P., India
b Maharaja Surajmal Institute of Pharmacy C-4, Janakpuri, New Delhi-58, IndiaReceived 13 April 2011; accepted 21 December 2012
Available online 31 December 2012KEYWORDS
Pyrimidine;
Chalcone;
Anti-inﬂammatory activityAbstract A new series of 4, 6-substituted di-(phenyl) pyrimidin-2-amine (IIa–d) were synthesized
by reacting chalcone derivatives with guanidine hydrochloride in the presence of dimethylformam-
ide. The synthesized compounds were characterized by spectral analysis and were screened for
anti-inﬂammatory activity. Two compounds 4-(4-nitrophenyl)-6-phenylpyrimidine-2-amine (IIa)
and 4-(4-methoxyphenyl)-6-phenylpyrimidine-2-amine (IIb) showed highly signiﬁcant reduction in
oedema volume
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Inﬂammation is a local reaction of the vascular tissue to injury
resulting in the formation of protein-rich exudates. The cardi-
nal signs of inﬂammation are rubor (redness), calor (heat),
dolor (pain), tumour (swelling), and functio laesa (loss of
function). Inﬂammation is caused by various agents such as
physical agents, chemical agents, immunological reactions,
and infection by pathogenic organism (Wilson et al., 2003).
Inﬂammation is of two types acute and chronic. The acute
inﬂammation is the exudation of ﬂuid and plasma proteins(oedema) and the emigration of leukocytes, especially neutro-
phils. Chronic inﬂammation is of prolonged duration in which
active inﬂammation, tissue destruction, and attempts at repair
are occurring simultaneously. Chronic inﬂammation includes
the most common diseases, such as rheumatoid arthritis, ath-
erosclerosis, tuberculosis, and chronic lung diseases (Collins
et al., 2001). Several pyrimidine derivatives have wide varieties
of usages and their nucleus is also present in vitamin B2 and
folic acid.
Pyrimidines are an important class of heterocyclic
compounds, which shows a wide range of pharmacological
activities such as antimicrobial (Gossnitzer et al., 2002),
anti-inﬂammatory (Hogale et al., 1986), anticancer (Mattew
et al., 1984), antiviral (Ahluwalia et al., 1987), antitubercular
(Jani et al., 1994) antihypertensive (Ishitsuka et al., 1982;
Ninomyia et al., 1990) and anticonvulsant (Calis and Koksal,
2001) activities. Along with these derivatives various research
papers showed that pyrimidine derivatives also have other
diverse pharmacological activities such as H1-antihistamines
(Alagarsamy et al., 2007) and 4-phosphodiesterase inhibitors
(Crespo et al., 1998).
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2.1. Materials and reagents
Melting points were determined by the open capillary method
and were uncorrected. IR spectra were recorded by the KBr
pellet technique using JACO FT/IR 410-spectrophotometer.
1HNMR spectra were recorded on Bruker model DPX 300
(300 MHz NMR) spectrometer in DMSO-d6/CDCl3 using
tetramethylsilane as an internal standard. The purity of the
synthesized compounds was analysed by thin-layer chromatog-
raphy using silica gel as the stationary phase. Compounds were
visualized by U.V. visualizing cabinet. Mass spectra were ob-
tained using a Kratos-AEI MS-902S instrument. All chemicals
used were analytical grade and puriﬁed before use in different
reactions.2.2. General procedure for synthesis of substituted chalcones
(Ia-d)
The substituted chalcones were prepared by reacting an equi-
molar quantity of aromatic aldehyde (0.01) and acetophenone
(0.01) in absolute ethanol; add 40% NaOH solution to the
reaction mixture drop wise with stirring maintaining the tem-
perature 0–2 C. After completion of the reaction the solid
was separated out and was poured into ice, the precipitate
was ﬁltered and recrystallized with ethanol. This leads to the
formation of substituted chalcones i.e. a, b unsaturated ke-
tones which were carried out by the clasien-schmidt condensa-
tion reaction.2.2.1. 1-(4-Nitrophenyl)-3-phenylprop-2-en-1-one (Ia)
Yield: 67%; mp: 122–124 C; IR (KBr cm1): 3067(Ar C-H
stretching), 1660 (C=C stretching), 1608 (Ar. C=C stretch-
ing), 1218 (Ar. C–O), 655(Ar. C–H bend) 1462 (–NO2 stretch-
ing); 1H NMR (DMSO): d 7.14–7.30 (m, 5H), 8.12–8.32 (m,
4H), 7.56–7.82 (s, 2H, oleﬁnic proton). Anal. Calcd for
C15H11NO3: C, 71.0; H, 4.26; N, 5.42; O, 18.75. Found: C,
71.14, H, 4.38, N, 5.53, O, 18.95.2.2.2. 3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (Ib)
Yield: 65.54%; mp: 80–82 C; IR (KBr cm1): 3061(Ar C–H
stretching), 1448(Ar C=C stretching), 1606 (C=C Stretching),
1215 (Ar–CO stretching), 748 (C–H vibrational).1157(–OCH3
stretching); 1HNMR (DMSO): d 6.72–7.13 (m, 4H), 7.65–
7.81 (m, 5H), 7.51–7.59 (s, 2H, oleﬁnic proton), 3.73 (s, 3H,
OCH3). Anal. Calcd. for C16H14O2: C, 80.56; H, 5.82; O,
13.36. Found: C, 80.65, H, 5.92 O, 13.43.2.2.3. 3-(4-Methoxyphenyl)-1-(4-nitrophenyl)prop-2-en-1-one
(Ic)
Yield: 78%; mp: 150–152 C; IR (KBr cm1): 3067(Ar C–H
stretching), 1663 (C=C stretching), 1608 (Ar. C=C stretch-
ing), 1218 (Ar. C–O), 655(Ar. C–H bend), 1462 (–NO2 stretch-
ing), 1166 (-OCH3 stretching);
1H NMR (DMSO): d 7.41-7.56
(s, 2H, oleﬁnic proton), 6.81–7.13 (m, 4H), 8.07–8.31 (m, 4H),
3.63 (s, 3H, OCH3). Anal. Calcd. for C16H13NO4: C, 67.82; H,
4.60; N, 4.84; O, 22.54. Found: C, 67.84; H, 4.63; N, 4.94; O,
22.59;2.2.4. 3-(4-Methoxyphenyl)-1-p-tolylprop-2-en-1-one (Id)
Yield: 63.2%; mp:174–176 C; IR (KBr cm1): 3162(Ar C–H
stretching), 1653 (C=C stretching), 1608 (Ar. C=C stretch-
ing), 1228 (Ar. C–O), 657 (Ar. C-H bend); 1H NMR (DMSO):
d 2.35 (s, 3H, –CH3), 3.71 (s, 3H, OCH3), 6.89–7.21 (m, 4H,
ArH), 7.45–7.69 (m, 4H, ArH), 7.82 (s, 2H, oleﬁnic proton).
Anal. Calcd. for C17H16O2: C, 80.86; H, 6.27; O, 12.62. Found
C, 80.93, H, 6.39, O, 12.68;
2.3. General procedure for Synthesis of 4, 6-substituted
di(phenyl)pyrimidin-2-amine derivatives (IIa-d)
Substituted pyrimidines were prepared by reﬂuxing an equimo-
lar quantity of substituted chalcones (0.01 mol) with guanidine
hydrochloride (0.01 mol) in the presence of dimethylformam-
ide (DMF) at 50–60 C for 6–7 h, the reaction mixture was
cooled and poured into crushed ice, kept overnight for com-
plete precipitation. The product was ﬁltered and recrystallized
with methanol and later was washed with petroleum ether
(Scheme 1).
2.3.1. 4-(4-Nitrophenyl)-6-phenylpyrimidine-2-amine (IIa)
Yield: 52.6%; mp: 180–182 C; I.R. (KBr, cm1) 3403 (C–H
aromatic stretching), 3322 (free NH2 stretching), 1627 (C=C
aromatic stretching), 1515 (C=N stretching), 755, 690 (C-H
aromatic bending). 1H NMR (DMSO): d 7.22–7.43 (m, 5H,
ArH), 7.74 (s, 2H, ArH), 8,25 (s, 2H, ArH), 6.89 (s, 1H, pyri-
midinyl proton), 4.21 (s, 2H, –NH2). MS (m/z): (292.10,
246.10, 231.09, 170.07, 155.06, 79.02, 53.02, 26.01). Anal.
Calcd for C16H12N4O2: C, 65.70; H, 4.10; N, 19.12; O, 10.88.
Found: C, 65.75, H, 4.14; N, 19.17; O, 10.95.
2.3.2. 4-(4-Methoxyphenyl)-6-phenylpyrimidine-2-amine (IIb)
Yield: 62.6%; mp: 212–214 C; IR(KBr, cm1) 3400 (C–H aro-
matic stretching), 3310 (free NH2 stretching), 1657 (C=C aro-
matic stretching), 1589 (C=N stretching), 1015 (C–O–C
stretching), 777, 689 (C–H aromatic bending). 1H NMR
(DMSO): d 7.22–7.41 (s, 5H, ArH), 6.81–7.11 (m, 4H, ArH),
6.81 (s, 1H, pyridinyl proton), 3.71 (s, 3H, OCH3), 3.81 (s,
3H, NH2). MS(m/z): (277.12, 246.13, 231.09 170.07, 155.06,
94.04, 79.02, 53.02, 26.01)Anal. Calcd. for C17H15N3O: C,
73.60; H, 5.35; N, 15.10; O, 5.72. Found: C, 73.63, H, 5.45,
N, 15.15, O, 5.77.
2.3.3. 4-(4-Methoxyphenyl)-6-(4-nitrophenyl) pyrimidin-
2-amine: (IIc)
Yield: 59.9%; mp: 190-192 C; IR(KBr, cm1) 3450 (C-H aro-
matic stretching), 3328 (free NH2 stretching), 1657 (C=C aro-
matic stretching), 1581 (C=N stretching), 1033 (C-O-C
stretching), 721, 697(C-H aromatic bending). 1H
NMR(DMSO): d 6.85-7.21 (m, 4H, ArH), 7.79-8.12 (m, 4H,
ArH), 6.86 (s, 1H, pyridinyl proton), 3.69 (s, 3H, OCH3),
4.12 (s, 2H, NH2). Anal. Calcd. for C17H14N4O3: C, 63.30;
H, 4.32; N, 17.32; O, 14.82. Found: C, 63.35, H, 4.38, N,
17.38; O, 14.89.
2.3.4. 4-(4-Methoxyphenyl)-6-p-tolylpyrimidin-2-amine (IId)
Yield: 55.5%; mp: 222-224 C; IR (KBr, cm1) 3480 (C-H
stretching aromatic), 3310 (free NH2 stretching), 1656 (C=C
aromatic stretching), 1510 (C=N stretching), 1033 (C–O–C
stretching), 672, 629 (C–H aromatic bending); 1H
NMR(DMSO): d 3.71 (s, 3H, OCH3), 2.34 (s, 3H, CH3),
CHO
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Scheme 1 Synthesis of 4, 6-substituted di-(phenyl) pyrimidin-2-amines derivatives.
Table 1 Anti-inﬂammatory activity data (paw volume) of
synthesized compounds
COMPOUND CODE MEAN(oedema volume)±SEM
1 h 3 h
Std 0.26±0.02 0.50±0.026
IIa 0.20±0.025 0.22±0.028***a
IIb 0.35±0.040 0.25±0.035***
IIc 0.28±0.030 0.36±0.020*
IId 0.43±0.045* 0.45±.044
All the synthesized compounds were screened for their antiinﬂam-
matory activity by the carrageenan induced rat paw oedema
method at a dose of 10 mg/kg body weight and mean of oedema
volume is given in table. It was observed that compounds IIa and
IIb showed a highly signiﬁcant reduction in oedema after 3hr.
a All the values are expressed as Mean ± SEM of six animals in
each group. ***(p 6 0.001) indicates the level of statistical
signiﬁcance.
Figure 1 Anti-inﬂammatory activity of synthesized compounds.
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inyl proton). Anal. Calcd. for C18H17N3O: C, 74.18; H, 5.82;
N, 14.38; O, 5.42. Found: C, 74.20, H, 5.88, N, 14.42, O, 5.49.
Reagents and conditions: (i) Absolute ethanol, 40%NaOH,
stirring 3-4 hrs at 0-2 C (ii) Guanidine hydrochloride, DMF,
reﬂux for 6-7 hrs at 50-60 C.
3. Results and discussion
3.1. Chemistry
Firstly aromatic aldehyde was treated with acetophenone and
sodium hydroxide to obtain substituted chalcone. Then the ti-
tle compounds (IIa-d) were successfully obtained by substi-
tuted chalcone and guanidine hydrochloride. Compounds
(IIa-d) were characterized by IR, 1HNMR and elemental anal-
ysis. All results are in full agreement with the proposed struc-
ture. For example 1H NMR spectrum showed the most
important signal at d 7.75 pspm for pyrimidinyl moiety and
different other signals were observed at the expected chemical
shift. IR spectra showed the absorption band in the region of
1510-1599 cm1assigned for aromatic C=N stretching and
3310–3328 cm1assigned for free –NH2 which plays an impor-
tant role in the formation of pyrimidine moiety.
3.2. Anti-inﬂammatory activity
All the synthesized compounds were screened for their antiin-
ﬂammatory activity. Antiinﬂammatory activity is performed in
albino rats using the carrageenan induced rat paw oedema
method (Winter et al.,1962) at a dose of 10 mg/kg body weight.
The test compounds were made into homogeneous suspension
with distilled water and 1%CMC solution and were adminis-
tered orally. The oedema volume was noted at the end of the
1st and 3rd hr of administration of carrageenan and the test
compound was compared with known standard(Indometha-
cin). The anti-inﬂammatory activity of all the synthesized com-
pounds (Ia-d) is presented in Table 1. All compounds were
tested at a dose of 10 mg/kg p.o. and have shown considerable
anti- inﬂammatory activity in Fig. 1. From Fig. 1, we could
ﬁnd these compounds showed signiﬁcant anti-inﬂammatory
activities. Compounds with the electron withdrawing groupat the 4th position such as IIa increased the activity and com-
pounds with electron donating groups such as IId decreased
the activity.
3.3. Statistical analysis
Anti-inﬂammatory activity of synthesized compounds was
measured by rat paw edema method using plethysmometer.
S880 N. Kumar et al.All the values are expressed as Mean ± SEM and ***p< 0.001
indicates the level of signiﬁcance compared with standard. Sta-
tistical analysis was performed by one way-ANOVA and post
hoc analysis was done by tukey’s test.
4. Conclusions
All the newly synthesized 4, 6-substituted di-(phenyl) pyrimi-
din-2-amine derivatives were tested in-vivo in order to evaluate
their anti-inﬂammatory activity by the carrageenan induced
rat paw oedema method. Compound having the electron
withdrawing group increased the activity. It was observed that
compounds IIa and IIb showed a highly signiﬁcant reduction in
oedema after 3hr whereas compounds IIc and IId showed
a less signiﬁcant reduction in oedema volume. All the tested
compounds were compared with standard drug Indomethacin.Acknowledgement
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